1. Home
  2. RGLS vs PROP Comparison

RGLS vs PROP Comparison

Compare RGLS & PROP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • PROP
  • Stock Information
  • Founded
  • RGLS 2007
  • PROP 2001
  • Country
  • RGLS United States
  • PROP United States
  • Employees
  • RGLS N/A
  • PROP N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • PROP Investment Bankers/Brokers/Service
  • Sector
  • RGLS Health Care
  • PROP Finance
  • Exchange
  • RGLS Nasdaq
  • PROP Nasdaq
  • Market Cap
  • RGLS 102.1M
  • PROP 115.3M
  • IPO Year
  • RGLS 2012
  • PROP N/A
  • Fundamental
  • Price
  • RGLS $1.44
  • PROP $8.70
  • Analyst Decision
  • RGLS Strong Buy
  • PROP
  • Analyst Count
  • RGLS 6
  • PROP 0
  • Target Price
  • RGLS $10.33
  • PROP N/A
  • AVG Volume (30 Days)
  • RGLS 493.3K
  • PROP 105.4K
  • Earning Date
  • RGLS 11-07-2024
  • PROP 01-01-0001
  • Dividend Yield
  • RGLS N/A
  • PROP N/A
  • EPS Growth
  • RGLS N/A
  • PROP N/A
  • EPS
  • RGLS N/A
  • PROP N/A
  • Revenue
  • RGLS N/A
  • PROP $1,545,792.00
  • Revenue This Year
  • RGLS N/A
  • PROP $5,586.66
  • Revenue Next Year
  • RGLS N/A
  • PROP $244.90
  • P/E Ratio
  • RGLS N/A
  • PROP N/A
  • Revenue Growth
  • RGLS N/A
  • PROP N/A
  • 52 Week Low
  • RGLS $1.08
  • PROP $5.27
  • 52 Week High
  • RGLS $3.79
  • PROP $16.55
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 41.95
  • PROP 46.92
  • Support Level
  • RGLS $1.36
  • PROP $7.70
  • Resistance Level
  • RGLS $1.65
  • PROP $8.43
  • Average True Range (ATR)
  • RGLS 0.10
  • PROP 0.53
  • MACD
  • RGLS -0.01
  • PROP -0.04
  • Stochastic Oscillator
  • RGLS 28.57
  • PROP 31.28

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About PROP Prairie Operating Co.

Prairie Operating Co develops and operates bitcoin mining scaled-up facilities using natural gas to power the operations. It generates substantially all its revenue through cryptocurrency, which it earns through mining activities.

Share on Social Networks: